Somewhat Positive News Coverage Somewhat Unlikely to Affect Neovasc (NVCN) Share Price
Press coverage about Neovasc (NASDAQ:NVCN) (TSE:NVC) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Neovasc earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 45.9670502321296 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Neovasc Inc. (NVCN) Set to Announce Quarterly Earnings on Tuesday (americanbankingnews.com)
- Neovasc (NVCN) Prices 6.609M Series A Unit and 19.07M Series B Unit Common Share/Warrant Offering at $1.46/Unit (streetinsider.com)
- Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants (finance.yahoo.com)
- Neovasc to Host Third Quarter 2017 Conference Call (finance.yahoo.com)
- Tracking Technical Indicators on Neovasc Inc. (NVCN) – Wall Street Morning (wallstreetmorning.com)
Separately, Zacks Investment Research lowered shares of Neovasc from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th.
Neovasc (NASDAQ:NVCN) opened at $1.01 on Tuesday. Neovasc has a fifty-two week low of $0.47 and a fifty-two week high of $3.34. The company has a market cap of $82.86, a PE ratio of 5.00 and a beta of 0.27.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/14/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-neovasc-nvcn-share-price.html.
Neovasc Company Profile
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.